Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Neurosci ; 23(25): 8673-81, 2003 Sep 24.
Artículo en Inglés | MEDLINE | ID: mdl-14507966

RESUMEN

Lissencephaly is a severe brain malformation caused by impaired neuronal migration. Lis1, a causative gene, functions in an evolutionarily conserved nuclear translocation pathway regulating dynein motor and microtubule dynamics. Whereas microtubule contributions to neuronal motility are incompletely understood, the actin cytoskeleton is essential for crawling cell movement of all cell types investigated. Lis1 haploinsufficiency is shown here to also result in reduced filamentous actin at the leading edge of migrating neurons, associated with upregulation of RhoA and downregulation of Rac1 and Cdc42 activity. Disruption of RhoA function through pharmacological inhibition of its effector kinase, p160ROCK, restores normal Rac1 and Cdc42 activity and rescues the motility defect in Lis1+/- neurons. These data indicate a previously unrecognized role for Lis1 protein in neuronal motility by promoting actin polymerization through the regulation of Rho GTPase activity. This effect of Lis1 on GTPases does not appear to occur through direct Lis1 binding of Rho, but could involve Lis1 effects on Rho modulatory proteins or on microtubule dynamics.


Asunto(s)
Movimiento Celular/genética , Citoesqueleto/metabolismo , Proteínas Asociadas a Microtúbulos/deficiencia , Neuronas/fisiología , Proteínas de Unión al GTP rho/metabolismo , 1-Alquil-2-acetilglicerofosfocolina Esterasa , Actinas/metabolismo , Animales , Animales Recién Nacidos , Inhibición de Migración Celular , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Citoesqueleto/patología , Inhibidores Enzimáticos/farmacología , Fibroblastos/citología , Fibroblastos/efectos de los fármacos , Fibroblastos/fisiología , Regulación de la Expresión Génica , Heterocigoto , Péptidos y Proteínas de Señalización Intracelular , Ratones , Proteínas Asociadas a Microtúbulos/genética , Malformaciones del Sistema Nervioso/genética , Neuronas/citología , Neuronas/efectos de los fármacos , Fosfolipasas A/metabolismo , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/metabolismo , Proteína de Unión al GTP cdc42/metabolismo , Proteína de Unión al GTP rac1/metabolismo , Proteínas de Unión al GTP rho/genética , Quinasas Asociadas a rho
2.
J Invest Dermatol ; 134(5): 1265-1275, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24288007

RESUMEN

Skin-derived dendritic cells (DCs) are potent antigen-presenting cells with critical roles in both adaptive immunity and tolerance to self. Skin DCs carry antigens and constitutively migrate to the skin-draining lymph nodes (LNs). In mice, Langerin-CD11b- dermal DCs are a low-frequency, heterogeneous, migratory DC subset that traffics to LNs (Langerin-CD11b- migDCs). Here, we build on the observation that Langerin-CD11b- migDCs are Fms-like tyrosine kinase 3 ligand (Flt3L) dependent and strongly Flt3L responsive, which may relate them to classical DCs. Examination of DC capture of FITC from painted skin, DC isolation from skin explant culture, and from the skin of CCR7 knockout mice, which accumulate migDCs, demonstrate these cells are cutaneous residents. Langerin-CD11b- Flt3L-responsive DCs are largely CD24(+) and CX3CR1(low) and can be depleted from Zbtb46-DTR mice, suggesting classical DC lineage. Langerin-CD11b- migDCs present antigen with equal efficiency to other DC subsets ex vivo, including classical CD8α cDCs and Langerin+CD103+ dermal DCs. Finally, transcriptome analysis suggests a close relationship with other skin DCs, and a lineage relationship with other classical DCs. This work demonstrates that Langerin- CD11b- dermal DCs, a previously overlooked cell subset, may be an important contributor to the cutaneous immune environment.


Asunto(s)
Células Dendríticas/citología , Células Dendríticas/inmunología , Proteínas de la Membrana/inmunología , Piel/citología , Piel/inmunología , Inmunidad Adaptativa/inmunología , Animales , Antígenos de Superficie/inmunología , Antígenos de Superficie/metabolismo , Antígeno CD11b/inmunología , Antígeno CD11b/metabolismo , Receptor 1 de Quimiocinas CX3C , Movimiento Celular/inmunología , Femenino , Tolerancia Inmunológica/inmunología , Lectinas Tipo C/inmunología , Lectinas Tipo C/metabolismo , Ganglios Linfáticos/citología , Ganglios Linfáticos/inmunología , Masculino , Lectinas de Unión a Manosa/inmunología , Lectinas de Unión a Manosa/metabolismo , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Receptores CCR7/genética , Receptores de Quimiocina/genética , Factores de Transcripción/inmunología , Factores de Transcripción/metabolismo
3.
Expert Rev Cardiovasc Ther ; 8(3): 373-91, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20222816

RESUMEN

Diabetes mellitus is the world's fastest growing disease with high morbidity and mortality rates, predominantly as a result of heart failure. A significant number of diabetic patients exhibit diabetic cardiomyopathy; that is, left ventricular dysfunction independent of coronary artery disease or hypertension. The pathogenesis of diabetic cardiomyopathy is complex, and is characterized by dysregulated lipid metabolism, insulin resistance, mitochondrial dysfunction and disturbances in adipokine secretion and signaling. These abnormalities lead to impaired calcium homeostasis, ultimately resulting in lusitropic and inotropic defects. This article discusses the impact of these hallmark factors in diabetic cardiomyopathy, and concludes with a survey of available and emerging therapeutic modalities.


Asunto(s)
Señalización del Calcio , Cardiomiopatías/fisiopatología , Complicaciones de la Diabetes/diagnóstico , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Mellitus Tipo 2/diagnóstico , Adipoquinas/metabolismo , Glucemia/metabolismo , Cardiomiopatías/tratamiento farmacológico , Cardiomiopatías/etiología , Complicaciones de la Diabetes/tratamiento farmacológico , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Femenino , Humanos , Resistencia a la Insulina , Metabolismo de los Lípidos/fisiología , Masculino , Mitocondrias Cardíacas/metabolismo , Mitocondrias Cardíacas/patología , Pronóstico , Medición de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA